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Patients with atopic dermatitis display substantial
immunologic abnormalities, among which elevated
total IgE is considered as a hallmark; however, a
subgroup of atopic dermatitis patients exhibits nor-
mal IgE levels, but mechanisms contributing to the
so-called ``intrinsic'' or ``nonallergic'' form of atopic
dermatitis are obscure. In order to unravel similar-
ities and differences of both atopic dermatitis sub-
types, the phenotype of monocytes, total serum IgE
levels, and serum levels of cytokines regulating the
IgE production from nonatopic individuals and
patients with allergic rhinitis, and extrinsic and
intrinsic atopic dermatitis were measured.
Concomitantly, genomic DNA probes of all subjects
were analyzed for single nucleotide polymorphisms
of candidate genes of structures involved in the regu-
lation of the IgE synthesis, such as interleukin-4 and
the interleukin-4R/interleukin-13R. Our data show
that the surface expression of the high- and low-
af®nity receptor for IgE (FceRI and FceRII/CD23)
and the interleukin-4Ra chain were signi®cantly ele-
vated in monocytes from patients with extrinsic ato-
pic dermatitis. Furthermore, serum levels of
interleukin-13 were signi®cantly increased in patients
with intrinsic atopic dermatitis. In addition, the fre-
quency of the interleukin-4Ra polymorphism
C3223T and the interleukin-4 polymorphism C590T
tended to be higher in extrinsic atopic dermatitis
than in intrinsic atopic dermatitis. Altogether our
®ndings indicate that intrinsic atopic dermatitis
patients exhibit phenotypic and immunologic fea-
tures, which differ from those of patients with
extrinsic atopic dermatitis or other atopic disorders.
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A
llergic rhinitis (AR), allergic bronchial asthma, and
atopic dermatitis (AD) are atopic diseases that develop
on a complex genetic background, the so-called
atopic diathesis. Although targeting different organs,
generally they are all characterized by the presence of
elevated total serum IgE levels combined with a less well de®ned
pharmacologic hyper-reactivity (Wollenberg et al, 2000). AD is a
common, chronic relapsing in¯ammatory skin disease, character-
ized by typically distributed eczematous skin lesions and intense
pruritus. Various names, such as atopic eczema, neurodermatitis
constitutionalis, endogenous eczema, eczema ¯exurarum, Besnier's
prurigo, asthma eczema, or hay fever eczema re¯ect the uncertainty
in the understanding of the pathophysiology of this disease
(Sulzberger, 1983; Schmid-Grendelmeier et al, 2001). The majority
of AD patients show high concentrations of total and allergen-
speci®c IgE in the blood and the skin. This form has been
individualized as the ``allergic'' or ``extrinsic'' form of AD (EAD)
(Bos et al, 1998). In the so-called ``nonallergic'' or ``intrinsic'' form,
also known as nonallergic atopiform eczema or nonallergic
atopiform dermatitis (IAD), which has been reported to represent
10±30% of all AD patients, patients have normal total serum IgE
levels and no allergen-speci®c IgE, although exhibiting the same
clinical phenotype. This suggests that elevated allergen-speci®c IgE
levels are not a prerequisite in the pathogenesis of IAD and key
mechanisms contributing to this subtype of AD are still unknown
(Werfel and Kapp, 1999). Therefore, the putative pathophysiologic
mechanisms involved in the development of IAD have been
studied by different research groups. A hallmark of IAD, is a lower
FceRI expression of CD1a+ epidermal dendritic cells.
Furthermore, a speci®c ratio of FceRI to FcgRII/CD32 on these
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cells could be used as diagnostic tool to differentiate between IAD
and EAD (Oppel et al, 2000). Akdis et al (1999) reported that skin
derived T cells from EAD give effective B cell help for IgE
production, whereas T cells from IAD patients do not. Recently,
the presence of autoantibodies directed against human proteins in
sera from patients with AD has been reported (Valenta et al, 1996).
The release of autoallergens from damaged tissue could trigger
allergic responses, but these autoantibodies have been found
exclusively in patients with elevated total serum IgE levels.
Interestingly, rare positive atopy patch tests have been observed
in some cases of IAD and point to the importance of T cell
mediated reactions and the development of the typical eczematous
skin lesions even in the absence of elevated serum IgE levels in
these patients (Ring et al, 2001).
Among others, the concept of an intrinsic defect at the level of
monocytic cells in atopic patients has long been the issue of
intensive research work. The putative link between monocytic cells
in the peripheral blood, a distinct atopic in¯ammatory reaction in a
target tissue (i.e., AD skin) and the genetic background of the
patients on the other hand, however, remained unclear.
These observations prompted us to reconsider monocytes from
atopic individuals under a different aspect and to correlate
differences detected in clinical and immunologic analyses in vitro,
with the genetic background of the patients. Therefore, potential
candidate genes (Cookson, 1999; Forrest et al, 1999), which are
closely related to pathways involved in the regulation of IgE were
screened for single nucleotide polymorphisms (SNP). IAD was
diagnosed by: (i) a clinical phenotype of AD; (ii) ful®lling the
diagnostic criteria of Hani®n and Rajka (1980); and (iii) low or
moderate total serum IgE levels (< 150 kU per liter) in combin-
ation with negative in vitro IgE screening for aeroallergens and food
allergens (e.g., CAP-RAST) as well as negative prick test results for
standard aeroallergens and food allergens and the absence of other
atopic diseases, such as allergic rhinoconjunctivitis or allergic
bronchial asthma (Schmid-Grendelmeier et al, 2001). The atopic
status and the disease severity were quanti®ed using the Diepgen
score (1996) and the SCORAD system (Diepgen et al, 1993),
respectively. The same physician did the complete clinical scoring
of all donors. Patients on ultraviolet therapy, on systemic or local
glucocorticosteroid treatment were excluded from this study.
Blood samples from AR patients were taken during the pollen
season and AR patients on systemic therapy were excluded from
the study.
MATERIALS AND METHODS
Reagents The monoclonal antibody (MoAb) 22E7 (a kind gift from
Dr J.P. Kochan and Dr R. Chizzonite, Roche Inc., Nutley, NJ)
recognizes the FceRI a-subunit (Riske et al, 1991). MoAb speci®c for
FceRII/CD23 were clones MHM6 (DAKO, Glostrup, Denmark) and
9P.25 (Jackson, West Grove, PA). MoAb speci®c for CD40 clone (5C3)
was from Immunotech (Marseille, France) and the MoAb speci®c for the
a-chain of the interleukin (IL)-4R (CD124), clone S4-56C9 was from
Immunotech. Fluorescein isothiocyanate-labeled F(ab¢)2. Fragments of
goat anti-mouse were purchased from Dianova (Hamburg, Germany).
Phycoerythrin-labeled MoAb against CD14, CD80, CD86, HLA-DR,
and mouse IgG1 were from Becton Dickinson (Mountain View, CA).
The MoAb against CD1a (T6RD1) was from Coulter Clone (Miami,
Florida). The hybridoma cell line that produces MoAb W6/32 against
major histocompatibility complex class I (Barnstable et al, 1978) was
kindly provided by Dr N. Koch (Institute of Zoophysiology, University
of Bonn). The MoAb anti-CD83 and anti-human mannose receptor
were from Becton Dickinson. Very Low Endotoxin RPMI 1640
medium was from Biochrom (Berlin, Germany). All other chemicals
were from Sigma (St Louis, MO) unless otherwise indicated.
Monocyte isolation Monocytes were isolated from peripheral blood
with a modi®ed density gradient protocol using Nycoprepâ (Nycomed,
Oslo, Norway) according to the manufacturer's instructions as described
previously (Novak et al, 2001a). The purity of the cells was evaluated by
¯ow cytometry and was > 95% CD14+ cells.
Flow cytometric analysis Labeling was performed as reported
previously in detail (Novak et al, 2001b). The viable CD14+ monocytic
cell population was analyzed on a FACSCalibur (Becton Dickinson). For
quantitative evaluation, two-dimensional dot plot analysis was performed
and the CD14 population was gated manually by a combination of
forward and side scatter and FL2/FL3 (CD14/7AAD) gates. The mean
¯uorescence intensities were determined by Cell-Quest software (Becton
Dickinson).
Enzyme-linked immunosorbent assay Serum samples were
collected in separator tubes and allowed to clot for 30 min before
centrifugation for 10 min at approximately 1000 3 g, then they were
stored at ±20°C.
Enzyme-linked immunosorbent assays were done according to the
manufacturer's instructions (R&D Systems, Wiesbaden, Germany).
Isolation of genomic DNA Genomic DNA was isolated from
peripheral blood as reported elsewhere. The whole blood was lyzed
(Kruse et al, 1999a, 1999b) washed and digested with proteinase K
(Roche, Basel, Switzerland). After digestion, the solution was extracted
two times with ethanol. DNA was ethanol precipitated and resuspended
in Tris buffer.
Restriction fragment-length polymorphisms analysis Polymerase
chain reaction for genotyping was performed with mutated primers
introducing a restriction site for restriction fragment-length poly-
morphisms analysis in dependence on the respective genotype. As
suggested by the Nomenclature Working Group (Antonarakis, 1998)
single letter amino acid codes were used referring to the wild-type IL-
4Ra mature protein sequence as published by Idzerda et al (1990). The
primer pairs used for the restriction fragment-length polymorphisms
analysis are shown in Table I (Noguchi et al, 1998; Kruse et al, 1999a).
Polymerase chain reaction was carried out in a volume of 10 ml
containing 30 ng DNA, 5 pmol of each primer, 0.06 U Taq polymerase
(Pharmacia, Uppsala, Sweden); 2 mmol deoxyribonucleoside triphosphate
mix. Annealing temperatures were 55°C for IL-4 C590T and IL-13
R110Q; 59°C for S478P; 60°C for I50V, Q551R, and S761P; 62°C for
C406R and C3223T; 64°C for E375A. Restriction was performed in a
volume of 10 ml containing 5 ml of the polymerase chain reaction
product and the buffer recommended by the supplier for 90 min at 37°C
or 65°C. Enzymes were purchased from NEB (Frankfurt, Germany) or
Pharmacia (Freiburg, Germany). The fragments were resolved on 10% or
12% polyacrylamide gels. In each reaction individuals with known
genotypes were included as positive and negative controls. The geno-
typing was performed by two investigators unaware of the phenotype.
Statistical analysis Statistical analysis using Wilcoxon's test was
performed with SPSS 9.0 for Windows (SPSS, Chicago, IL). Calculated
values shown were percentage positive cells or mean 6 SEM.
Table I. Summary of the primer pairs used for the analysis
of the IL-4R/IL-13R and IL-4 polymorphisms.
IL-4R
I50V 5¢-GCCTCCGTTGTTCTCAGGTA-3¢
5¢-TCTGTCCTCGCATCCGTGAT-3¢
BstZ17I
E375A 5¢-TTAGCCGGGCCACAAAGGCC-3¢
5¢-TGGAGATCAGCAAGACAGTC-3¢
StuI
C406R 5¢-TGTGGCCCGGCTAACAGAGA-3¢
5¢-AGGGTTGCCTGCGATGACGA-3¢
Tsp45I
S478P 5¢-CTTACCGCAGCTTCAGGTAC-3¢
5¢-TTTCTGGCTCAGGTTGGGGC-3¢
KpnI
Q551R 5¢-GGCCCCACCAFTGGCGATC-3¢
5¢-GCAAGCAGGCTTGAGAAGGC-3¢
PvuI
S761P 5¢-CCCTGGCACCCTCGGGGATC-3¢
5¢-CCTGGCTGCCTTCCAGGAGG-3¢
BamHI
C3223T 5¢-TGGACCTGCTCCCAGGCATCGA-3¢
5¢-AGGGCATTGTTCTCGGGTGCA-3¢
ClaI
IL-4
C590T 5¢-TAAACTTGGGAGAACATGGT-3¢
5¢-TGGGGAAAGATAGAGTAATA-3¢
AvaII
IL-13R
R110Q 5¢-TGGCGTTCTACTCACGTGCT-3¢
5¢-TTTCGAAGTTTCAGTGGAAC-3¢
NlaIV
VOL. 119, NO. 4 OCTOBER 2002 THE DICHOTOMY OF EXTRINSIC AND INTRINSIC ATOPIC DERMATITIS 871
Additionally, the frequencies of the genotypes between the different
groups were compared using the Cochran±Armitage Trends test (Slager
and Schaid, 2001).
RESULTS
Clinical characteristics of IAD and EAD patients The data
comparing patients with AR, IAD, and EAD are summarized in
Table II. Altogether, there were no signi®cant differences in the
extent of the affected surface, the onset of the disease in IAD and
EAD patients. Interestingly, there was a clear female predominance
in IAD patients in our study (Table II).
FceRI, FceRII, and IL-4Ra expression is upregulated in
EAD but not in IAD Monocytes from patients with EAD and
IAD display the high-af®nity receptor for IgE (FceRI), low-af®nity
receptor for IgE (FceRII) and IL-4Ra in a distinct manner on their
cell surface (Fig 1A). As shown in Fig 1B, monocytes from all
atopic individuals express higher amounts of CD40 in contrast to
healthy, nonatopic donors. In addition, the expression of the high-
af®nity receptor for IgE (FceRI) and the low-af®nity receptor for
IgE (FceRII/CD23) were signi®cantly upregulated in patients with
AR and EAD. IL-4Ra was low on monocytes of nonatopic donors
and patients with IAD, whereas monocytes from patients with AR
and EAD expressed enhanced levels of IL-4Ra. In summary,
freshly isolated monocytes from patients with EAD and IAD
displayed signi®cant immunophenotypical differences.
Serum levels of IL-13 are elevated in IAD, whereas IL-5
serum levels are higher in EAD patients To correlate the
immunophenotypical differences of peripheral blood monocytes
and IgE serum levels, serum levels of cytokines involved in the IgE
synthesis have been evaluated. As shown in Fig 2, patients with
AR had signi®cantly elevated IL-4 and IL-13 serum levels, whereas
in EAD patients, IL-4 was only slightly elevated. Interestingly, the
amount of IL-13 in the sera of IAD patients was signi®cantly
enhanced compared with patients with EAD (p < 0.05). In
contrast, IL-5 serum levels were higher in patients with EAD
than in IAD patients and normal controls (nonatopic donor)
(p < 0.05). In addition, all of the atopic patients displayed an
enhanced serum level of the soluble form of the IL-4Ra (sIL-4R)
(p < 0.05), without signi®cant differences in the serum level of the
sIL-4R between the different atopic donor groups (Fig 2).
The frequency of the IL-4Ra promoter polymorphism
C3223T and the IL-4 C590T polymorphism is higher in
EAD than in IAD In order to investigate, whether the
differences in the IL-4Ra surface expression of monocytes from
patients with IAD might result from genomic variations, genomic
DNA probes from all patients were investigated for SNP of the IL-
4Ra/IL-4 and for IL-13R as these have been shown to play a
relevant part in atopic diseases before (Cookson, 1998; 1999;
Forrest et al, 1999; Heinzmann et al, 2000; Kruse et al, 1999a,b).
The promoter polymorphism of IL-4Ra C3223T and the IL-4
protein (C590T) tended to be present more often in EAD than in
IAD. For the other polymorphisms investigated, no signi®cant
differences in the frequencies could be detected (Table IIIA,B).
DISCUSSION
Whereas it is assumed that IgE and FceRI expressed on antigen-
presenting cells play a pivotal role in the pathogenesis of EAD
(Bieber, 1997; Wollenberg et al, 2000; Novak et al, 2001a, Novak
et al, 1999), the mechanisms underlying the skin in¯ammation in
IAD remain elusive. In our collective, with regard to the clinical
phenotype, the age of onset and the duration of the disease, IAD
and EAD patients do not differ signi®cantly. In the literature,
peripheral blood T cell activation and peripheral blood eosinophilia
were described in both groups, whereas elevated levels of serum
IgE and FceRII/CD23+ B cells were found exclusively in EAD
(Schmid-Grendelmeier et al, 2001). In contrast, CD4+ and CD8+ T
cells expressed increased activation markers (HLA-DR and CD25)
in both, IAD and EAD patients (Akdis et al, 1999). These data are
consistent with the ®nding that in contrast to nonatopic controls,
monocytes derived from patients with atopic diseases show signs of
activation, e.g., an increased surface expression of costimulatory
molecules such as CD40 in our study. In addition, the surface
expression of FceRI and FceRII/CD23 is low on monocytes from
patients with IAD, similar to CD1a+ epidermal dendritic cells of
patients with IAD, which exhibit a low surface expression of FceRI
(Oppel et al, 2000).
One possible explanation of these differences might be the
reduced surface expression of the extracellular part of the IL-4Ra
chain detected in this study. It is known that IL-4 plays a pivotal
role in upregulating IgE receptors on human monocytes and
dendritic cells and the low IL-4Ra surface expression might be of
pathophysiologic relevance in this context (Geiger et al, 2000;
Reischl et al, 2000). It is known that IL-4 and the closely related
cytokine IL-13 share many biologic and immunoregulatory
functions. The IL-4Ra chain is a common component of both,
the IL-4 and the IL-13 receptor (Chomarat and Banchereau, 1997,
1998). In our study, patients with AD and high IgE production,
show the C3223T allele of the IL-4Ra promoter region and the
C590T allele of the IL-4 promoter more frequently than patients
with AD and normal total IgE. These data are in line with the
association between the IL-4 promoter C590T and enhanced total
serum IgE levels, which has been reported by Rosenwasser et al
(1995) and Klein et al (2001). Similar to the recently published data
of Tanaka et al (2001) we could not detect any signi®cant difference
in the frequency of polymorphisms of the extracellular IL-4Ra
(I50V) in patients with IAD and EAD; however, it should be noted
that due to the restrictive criteria to classify IAD and the low
number of IAD patients, the differences between IAD and EAD
presented here are based on descriptive statistical analyses, which do
not take into account multiple corrections. The preliminary trend
analysis provided here, should enable us to take putative
genotypical variations into consideration, which might underlie
the phenotypical and immunologic differences of IAD and EAD
patients observed in this study. Furthermore, no differences in the
serum level of the soluble form of the IL-4Ra could be found
between the different atopic donor groups, excluding an enhanced
shedding of this structure from the surface of monocytes of IAD
patients. Interestingly, the reduced IL-4Ra expression of mono-
cytes leads to a disturbed cellular response to IL-4 of these cells as
witnessed by a lower expression of FceRII/CD23 on IL-4/GM-
CSF driven monocyte-derived dendritic cells from patients with
IAD, when these cells were cultured with low doses of IL-4
(unpublished observation). This observation might link to a general
hyporesponsiveness to IL-4 in IAD patients in vivo.
The pathophysiologic mechanisms leading to the increased IL-13
production in the absence of high IgE levels in the sera of IAD
patients found in this study are completely elusive. It might be that
an additional factor driving the IgE synthesis is missing or blocked
in IAD (Simon et al, 2002) and IL-13 is directly or indirectly
involved in the pathogenesis of the disease by the stimulation of
Table II. Summary of the clinical characteristics of the
patients.
AR (n = 16) EAD (n = 60) IAD (n = 14)
Age (y) 24.2 (19-49) 31.3 (12-72) 31.5 (12-62)
Onset of disease
in early childhood
25% 90% 89%
Sex (female/male) 8/8 21/39 14/0
Allergic rhinitis 100% 53% 0%
Allergic asthma 25% 10% 0%
Diepgen Score ± 19.9 6 5.74 18.2 6 7.3
SCORAD ± 57.7 6 20.18 52 6 18.4
Positive family
history of atopy
100% 82% 70%
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eosinophils and interactions with B cells or alterations of the IL-
13R signal transduction pathway, which have to be characterized in
more detail in the future. IL-13 producing T cells, which could be
found in the cord blood of atopic children (Ohshima et al, 2002),
underline the hypothesis that this cytokine might play a crucial part
in the development of atopic diseases. Furthermore, IL-5, which
Figure 1. Upregulation of the FceRI, FceRII, and IL-4Ra expression of monocytes in EAD but not in IAD. (A) The surface expression of
the high-af®nity receptor for IgE (FceRI), low-af®nity receptor for IgE (FceRII), CD40, and the IL-4Ra chain of freshly isolated monocytes of
patients with EAD (upper panel) and IAD (lower panel) is shown as an overlay histogram. The logarithmic ¯uorescence intensity is indicated on the
x-axis, the cell count is indicated on the y-axis. One representative experiment of each group is given, EAD n = 60; IAD n = 14. (B) The expression
of the surface markers of freshly isolated monocytes of all donors evaluated are summarized and indicated on the y-axis as percentage positive cells
6 SEM; *p < 0.05; **p < 0.001. AR (black bars) n = 16; EAD (gray bars) n = 60; IAD (hatched bars) n = 14; and normal controls (nonatopic donor)
(white bars) n = 10.
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has been reported to increase in the sera in correlation to the
severity of AD (Kondo et al, 2001), was exclusively elevated in
patients with EAD.
Altogether our data underline the hypothesis that patients with
IAD display characteristics that differ from the phenomena typically
seen in atopic disease. The dichotomic view of the pathophysiology
of AD has long been questioned in the absence of clear-cut data.
More recently, epidemiologic evidence accumulated in favor of a
new classi®cation and the European Academy of Allergy and
Clinical Immunology has acknowledged this point of view in a
position paper (Johansson et al, 2001). The term atopic eczema/
dermatitis syndrome has been coined and the terms allergic and
nonallergic atopic eczema/dermatitis syndrome were proposed.
The phenotypical differences of monocytes of atopic patients
reported here provide an additional diagnostic tool to distinguish
between the allergic and nonallergic form of atopic eczema/
dermatitis syndrome (Fig 3). The latter is in keeping with the
notion that a complex network of different properties on the
cellular, humoral, and immunologic level, which in combination
with varying exposures to environmental stimuli, in¯uence the
outcome of the allergic or nonallergic subtype of this disease.
In conclusion, the data presented here provide evidence for
immunologic and phenotypic differences of both forms of the
atopic eczema/dermatitis syndrome and contribute to place
monocytes under a new light in the complex pathophysiology of
this disease.
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